Bronchodilator response to inhaled beta-2 agonist and anticholinergic drugs in patients with bronchiectasis

J. Abu Hassan, S. Saadiah, H. Roslan, B. M Z Zainudin

    Research output: Contribution to journalArticle

    28 Citations (Scopus)

    Abstract

    Objective: An increase in incidence of reversible airflow obstruction and bronchial hyperresponsiveness occurs in patients with bronchiectasis. We conducted a study to assess the efficacy of bronchodilators in the treatment of bronchiectasis. Methodology: Twenty-four patients with confirmed bronchiectasis were studied. Each patient inhaled fenoterol 400 μg administered by metered dose inhaler via a spacer after a baseline lung function and a lung function test was repeated 30 min later. This was followed by a second dose of fenoterol 5 mg via nebulizer and another lung function test 30 min later. A repeat study was done at least 24 h later with ipratropium bromide 40 μg by metered dose inhaler and 500 μg by a nebulizer. Results: The results showed a significant improvement from baselines (mean percentage change ± SD) of peak expiratory flow rate (PEF) by 8.5 ± 8.72% and 15.3 ± 11.63%, forced expiratory volume in 1 s (FEV1) by 8.77 ± 9.69% and 10.2 ± 12.2% and forced vital capacity (FVC) by 10.25 ± 11.61% and 10.09 ± 10.88% after low- and high-dose fenoterol, respectively. The improvements after low- and high-dose ipratropium bromide for PEF, FEV1 and FVC were 9.89 ± 9.35% and 14.39 ± 12.82%, 9.38 ± 10.41% and 13.52 ± 17.09%, and 8.03 ± 10.85% and 9.63 ± 13.85%, respectively. Eleven patients (45.8%) responded to one or both bronchodilators significantly (>15% improvement in FEV1). Five patients (20%) responded to both, three (12%) to fenoterol alone and another three (12%) to ipratropium bromide alone. Conclusion: There is significant bronchodilator response in a subset of patients with bronchiectasis and patients with bronchiectasis should therefore undergo bronchodilator testing. Skin prick testing against a panel of nine allergens done on each individual yielded a positive result in 13 patients (54.2%).

    Original languageEnglish
    Pages (from-to)423-426
    Number of pages4
    JournalRespirology
    Volume4
    Issue number4
    DOIs
    Publication statusPublished - 1999

    Fingerprint

    Bronchiectasis
    Bronchodilator Agents
    Cholinergic Antagonists
    Fenoterol
    Ipratropium
    Pharmaceutical Preparations
    Forced Expiratory Volume
    Metered Dose Inhalers
    Peak Expiratory Flow Rate
    Nebulizers and Vaporizers
    Respiratory Function Tests
    Vital Capacity
    Allergens
    Lung
    Skin
    Incidence

    Keywords

    • Atopy
    • Bronchiectasis
    • Bronchodilator response

    ASJC Scopus subject areas

    • Pulmonary and Respiratory Medicine

    Cite this

    Bronchodilator response to inhaled beta-2 agonist and anticholinergic drugs in patients with bronchiectasis. / Hassan, J. Abu; Saadiah, S.; Roslan, H.; Zainudin, B. M Z.

    In: Respirology, Vol. 4, No. 4, 1999, p. 423-426.

    Research output: Contribution to journalArticle

    Hassan, J. Abu ; Saadiah, S. ; Roslan, H. ; Zainudin, B. M Z. / Bronchodilator response to inhaled beta-2 agonist and anticholinergic drugs in patients with bronchiectasis. In: Respirology. 1999 ; Vol. 4, No. 4. pp. 423-426.
    @article{4ef2dfe121a24c5fa198ed3dcdc7f55d,
    title = "Bronchodilator response to inhaled beta-2 agonist and anticholinergic drugs in patients with bronchiectasis",
    abstract = "Objective: An increase in incidence of reversible airflow obstruction and bronchial hyperresponsiveness occurs in patients with bronchiectasis. We conducted a study to assess the efficacy of bronchodilators in the treatment of bronchiectasis. Methodology: Twenty-four patients with confirmed bronchiectasis were studied. Each patient inhaled fenoterol 400 μg administered by metered dose inhaler via a spacer after a baseline lung function and a lung function test was repeated 30 min later. This was followed by a second dose of fenoterol 5 mg via nebulizer and another lung function test 30 min later. A repeat study was done at least 24 h later with ipratropium bromide 40 μg by metered dose inhaler and 500 μg by a nebulizer. Results: The results showed a significant improvement from baselines (mean percentage change ± SD) of peak expiratory flow rate (PEF) by 8.5 ± 8.72{\%} and 15.3 ± 11.63{\%}, forced expiratory volume in 1 s (FEV1) by 8.77 ± 9.69{\%} and 10.2 ± 12.2{\%} and forced vital capacity (FVC) by 10.25 ± 11.61{\%} and 10.09 ± 10.88{\%} after low- and high-dose fenoterol, respectively. The improvements after low- and high-dose ipratropium bromide for PEF, FEV1 and FVC were 9.89 ± 9.35{\%} and 14.39 ± 12.82{\%}, 9.38 ± 10.41{\%} and 13.52 ± 17.09{\%}, and 8.03 ± 10.85{\%} and 9.63 ± 13.85{\%}, respectively. Eleven patients (45.8{\%}) responded to one or both bronchodilators significantly (>15{\%} improvement in FEV1). Five patients (20{\%}) responded to both, three (12{\%}) to fenoterol alone and another three (12{\%}) to ipratropium bromide alone. Conclusion: There is significant bronchodilator response in a subset of patients with bronchiectasis and patients with bronchiectasis should therefore undergo bronchodilator testing. Skin prick testing against a panel of nine allergens done on each individual yielded a positive result in 13 patients (54.2{\%}).",
    keywords = "Atopy, Bronchiectasis, Bronchodilator response",
    author = "Hassan, {J. Abu} and S. Saadiah and H. Roslan and Zainudin, {B. M Z}",
    year = "1999",
    doi = "10.1046/j.1440-1843.1999.00215.x",
    language = "English",
    volume = "4",
    pages = "423--426",
    journal = "Respirology",
    issn = "1323-7799",
    publisher = "Wiley-Blackwell",
    number = "4",

    }

    TY - JOUR

    T1 - Bronchodilator response to inhaled beta-2 agonist and anticholinergic drugs in patients with bronchiectasis

    AU - Hassan, J. Abu

    AU - Saadiah, S.

    AU - Roslan, H.

    AU - Zainudin, B. M Z

    PY - 1999

    Y1 - 1999

    N2 - Objective: An increase in incidence of reversible airflow obstruction and bronchial hyperresponsiveness occurs in patients with bronchiectasis. We conducted a study to assess the efficacy of bronchodilators in the treatment of bronchiectasis. Methodology: Twenty-four patients with confirmed bronchiectasis were studied. Each patient inhaled fenoterol 400 μg administered by metered dose inhaler via a spacer after a baseline lung function and a lung function test was repeated 30 min later. This was followed by a second dose of fenoterol 5 mg via nebulizer and another lung function test 30 min later. A repeat study was done at least 24 h later with ipratropium bromide 40 μg by metered dose inhaler and 500 μg by a nebulizer. Results: The results showed a significant improvement from baselines (mean percentage change ± SD) of peak expiratory flow rate (PEF) by 8.5 ± 8.72% and 15.3 ± 11.63%, forced expiratory volume in 1 s (FEV1) by 8.77 ± 9.69% and 10.2 ± 12.2% and forced vital capacity (FVC) by 10.25 ± 11.61% and 10.09 ± 10.88% after low- and high-dose fenoterol, respectively. The improvements after low- and high-dose ipratropium bromide for PEF, FEV1 and FVC were 9.89 ± 9.35% and 14.39 ± 12.82%, 9.38 ± 10.41% and 13.52 ± 17.09%, and 8.03 ± 10.85% and 9.63 ± 13.85%, respectively. Eleven patients (45.8%) responded to one or both bronchodilators significantly (>15% improvement in FEV1). Five patients (20%) responded to both, three (12%) to fenoterol alone and another three (12%) to ipratropium bromide alone. Conclusion: There is significant bronchodilator response in a subset of patients with bronchiectasis and patients with bronchiectasis should therefore undergo bronchodilator testing. Skin prick testing against a panel of nine allergens done on each individual yielded a positive result in 13 patients (54.2%).

    AB - Objective: An increase in incidence of reversible airflow obstruction and bronchial hyperresponsiveness occurs in patients with bronchiectasis. We conducted a study to assess the efficacy of bronchodilators in the treatment of bronchiectasis. Methodology: Twenty-four patients with confirmed bronchiectasis were studied. Each patient inhaled fenoterol 400 μg administered by metered dose inhaler via a spacer after a baseline lung function and a lung function test was repeated 30 min later. This was followed by a second dose of fenoterol 5 mg via nebulizer and another lung function test 30 min later. A repeat study was done at least 24 h later with ipratropium bromide 40 μg by metered dose inhaler and 500 μg by a nebulizer. Results: The results showed a significant improvement from baselines (mean percentage change ± SD) of peak expiratory flow rate (PEF) by 8.5 ± 8.72% and 15.3 ± 11.63%, forced expiratory volume in 1 s (FEV1) by 8.77 ± 9.69% and 10.2 ± 12.2% and forced vital capacity (FVC) by 10.25 ± 11.61% and 10.09 ± 10.88% after low- and high-dose fenoterol, respectively. The improvements after low- and high-dose ipratropium bromide for PEF, FEV1 and FVC were 9.89 ± 9.35% and 14.39 ± 12.82%, 9.38 ± 10.41% and 13.52 ± 17.09%, and 8.03 ± 10.85% and 9.63 ± 13.85%, respectively. Eleven patients (45.8%) responded to one or both bronchodilators significantly (>15% improvement in FEV1). Five patients (20%) responded to both, three (12%) to fenoterol alone and another three (12%) to ipratropium bromide alone. Conclusion: There is significant bronchodilator response in a subset of patients with bronchiectasis and patients with bronchiectasis should therefore undergo bronchodilator testing. Skin prick testing against a panel of nine allergens done on each individual yielded a positive result in 13 patients (54.2%).

    KW - Atopy

    KW - Bronchiectasis

    KW - Bronchodilator response

    UR - http://www.scopus.com/inward/record.url?scp=0033396323&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0033396323&partnerID=8YFLogxK

    U2 - 10.1046/j.1440-1843.1999.00215.x

    DO - 10.1046/j.1440-1843.1999.00215.x

    M3 - Article

    C2 - 10612580

    AN - SCOPUS:0033396323

    VL - 4

    SP - 423

    EP - 426

    JO - Respirology

    JF - Respirology

    SN - 1323-7799

    IS - 4

    ER -